We know that clinical studies are pivotal to a company’s success and mitigating risks, so we aim to deliver a service that surpasses our client’s expectations.

Our wonderful clients are the reason we’re in business, working together to make an impact on human wellbeing.

Here are some of the great things they’ve said about us.

I worked first with Elpis as a colleague and have had no hesitation in hiring her on several occasions since through Barons Medical Consulting.

Elpis is a dedicated, detail-orientated individual who always goes the extra mile to deliver quality results.

– Vanessa Lee, Marketing Director, Veryan Medical

Elpis led the set up and management of a clinical trial for Abbott Vascular in Australia.

Her on the ground presence allowed us to work confidently with a remote clinical centre and patient population we would not otherwise have had access to.

Her market knowledge, pleasant, professional, and focused approach were essential to the success of the project. I was delighted to rely on her expertise and drive for this as well as other projects.

Key to including a clinical centre so distant from the European based office was the ease of access we had in contacting and working with Elpis throughout the project, the time difference was immaterial to her and she made herself completely accessible to us.

I’d have no hesitation in seeking out Barons Medical Consulting for the purpose of clinical trial or regulatory related work in the future. We found the relationship valuable and cost effective.

– Mairsil Claffey, Vice President Clinical, Quality and Regulatory Affairs at Neuravi

Barons Medical Consulting (BMC) is the Australian CRO for the GLOBAL Study (NCT01738828) sponsored by Global Genomics Group (G3). The GLOBAL Study is an international, multi-center, prospective landmark cardiovascular disease program using advanced cardiovascular imaging for precision phenotyping and a pan-omic approach to identify underlying genomic, proteomic, metabolomic, and lipidomic underpinnings of cardio-metabolic diseases in up to 10,000 patients worldwide.

We first engaged Elpis Barons from BMC when we were exploring Australia as study location had not yet identified any institutions or investigators for potential collaboration.  Elpis was quickly able assist us in establishing essential operational infrastructure in Australia and successfully identified and established relationships with 6 clinical institutions and their key opinion leaders.  All 6 institutions went on to become engaged study site participants in the GLOBAL program.

BMC was able negotiate contracts, make IRB submissions on our behalf, monitor and manage the GLOBAL study locally in Australia.  The monitoring of the GLOBAL study was extensive and the approach of BMC was to ensure patient safety and data integrity was always maintained. This gave us confidence and despite its remoteness, Australia played a critical role in achieving our study outcomes.

G3 is headquartered in Richmond, Virginia, USA, so having BMC manage the project with the professionalism, timeliness and sensitivity required to ensure compliance and successful execution of the investigational plans was essential. Elpis consistently made herself available outside normal business hours, ensuring communication was never uninterrupted.  This enabled G3 to always make the critical deadlines necessary for the various stages of study approval, execution and data analyses.  Elpis’s dedication to the program and leadership enabled G3 to overcome the significant time difference between the USA and Australia.

Elpis’ background as a senior executive in the Medtech industry was extremely valuable when we transitioned from clinical study execution to forming strategic partnerships in Australia.  Her professional network is invaluable and she continues to play a pivotal role in introductions made to Australian entities.  Her local knowledge, strategic eye, attention to detail, collaborative and professional approach provided us with the confidence we needed to include Australia in this pivotal study.

I would not hesitate to recommend or appoint BMC to conduct clinical studies on behalf of G3 for future clinical programs.

– Mr Bradley Brown, Co-Founder and Vice President, Clinical Affairs at Global Genomics Group LLC